Download PDF
Thromb Haemost 1965; 14(03/04): 473-489
DOI: 10.1055/s-0038-1654884
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

On the Natural Blood Coagulation Inhibitor System Investigations of Inhibitor Factors Based on Antithrombin Deficient Blood

O Egeberg
1   The Institute for Thrombosis Research, Medical Department A, University Hospital, Bikshospitalet, Oslo, Norway
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

Natural coagulation inhibitor factors were studied in sera, or in fractions of sera, from patients with congenital partial deficiency of antithrombin and from normal persons. In the patients’ sera the progressive antithrombin (antithrombin III) and heparin cofactor (antithrombin II) had both been measured around 50 per cent of normal level.

No decreased activity could be demonstrated in the patients’ sera as to antiprothrombinase, the inhibitor against blood intrinsic prothrombinase activity.

For anticonvertin, the inhibitor against the tissue convertin complex, the activity was found decreased to about the same level as that demonstrated for antithrombin III and II. The results lend strong support to the hypothesis that the activities measured as anticonvertin, antithrombin III and antithrombin II represent functions of the same blood protein, which on the other side appears to be distinct from antiprothrombinase. In accordance with this explanation, an antithrombin III concentrate had also antithrombin II and anticonvertin activity, and further, adsorption of a normal human serum with convertin appeared to specifically reduce its antithrombin III activity.

The inhibitor against activated antihemophilic C factor (AHC’ = activated f. XI) was studied in sera adsorbed with BaS04 and celite. The inhibitor activity was found at normal level in the patients’ sera, consistent with the view that anti-AHC’ is distinct from antithrombin III, II and from anticonvertin. No acceleration of the anti-AHC’ activity could be demonstrated after addition to the inhibition mixture of weak solutions of heparin.

The results are discussed.

 

  • References

  • 1 Berry G. G. Antithromboplastin : The degeneration of intrinsic thromboplastin in normal serum. J. clin. Path. 11: 39 1958;
    CrossrefPubMedGoogle Scholar
  • 2 Biggs R, Douglas A. S, MacFarlane R. G. The formation of thromboplastin in human blood. J. Physiol. (Lond) 119: 89 1953;
    CrossrefPubMedGoogle Scholar
  • 3 Davie E. W, Ratnoff O. D. Waterfall sequence for intrinsic blood clotting. Science 145: 1310 1964;
    CrossrefPubMedGoogle Scholar
  • 4 Deutsch E, Fuchs H. Natürlich vorkommende Koagulationsinhibitoren. Acta haemat. (Basel) 20: 97 1958;
    CrossrefPubMedGoogle Scholar
  • 5 Deutsch E, Mammen E. The inactivation of plasma-thromboplastin. Thrombos. Diathes. haemorrh. (Stuttg) 02: 324 1958;
    PubMedGoogle Scholar
  • 6 Egeberg O. Assay of antihemophilic A, B and C factors by one-stage cephalin systems. Scand. J. clin. Lab. Invest. 13: 140 1961; a.
    CrossrefPubMedGoogle Scholar
  • 7 Egeberg O. Acquired circulating anticoagulant in classical hemophilia. Scand. J. clin. Lab. Invest. 13: 535 1961; b.
    CrossrefPubMedGoogle Scholar
  • 8 Egeberg O. The blood coagulability in diabetic patients. Scand. J .clin. Lab. Invest. 15: 533 1963;
    CrossrefPubMedGoogle Scholar
  • 9 Egeberg O. Changes in hemostatic system associated with tendency to thrombosis. Report Xth Congr. Int. Soc. Haemat., Stockholm. 1964
    PubMedGoogle Scholar
  • 10 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombos. Diathes. haemorrh. (Stuttg) 13: 516 1965;
    PubMedGoogle Scholar
  • 11 Egli H, Kesselre K, Klesper R. Über die Inaktivierung von Blutthrombinase. Acta haemat. (Basel) 17: 338 1957;
    CrossrefPubMedGoogle Scholar
  • 12 Hensen A, Loeliger E. A. Antithrombin III. Its metabolism and its function in blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg) 09: 1 1963;
    PubMedGoogle Scholar
  • 13 Hermansky F, Vitek J. The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum. Experientia 16: 455 1960;
    CrossrefPubMedGoogle Scholar
  • 14 Hermansky F, Vitek J. Beitrag zur Problematik der Anti-Thromboplastine. Abstracts of the 8th Congr. Europ. Soc. Haemat. Wien 1961. 104 R. Spieß & Co; Wien: 1961
    Google Scholar
  • 15 Hjort P. F. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Convertin, accelerin, prothrombinase. Scand. J. clin. Lab. Invest. 09. Suppl. 27 1957
    PubMedGoogle Scholar
  • 16 Hjort P. F, Rapaport S. I, Owren P. A. A simple one-stage prothrombin assay using Russell’s viper venom in cephalin suspension. J. Lab. clin. Med. 46: 89 1955;
    PubMedGoogle Scholar
  • 17 Iatridis S. G, Ferguson J. H, latridis P. G, Maudlin R. Thrombogenic properties of surface factor; evidence for an anti-surface factor activity in canine plasma. Thrombos. Diathes. haemorrh. (Stuttg) 12: 35 1964;
    PubMedGoogle Scholar
  • 18 Jürgens J. Factor VII-inhibitor. A new physiological serum accelerator inactivation principle. Actahaemat. (Basel) 14: 57 1955;
    PubMedGoogle Scholar
  • 19 Lasch H. G. Über die Hemmung von Antithrombin durch Faktor VII. Dtsch. Arch. klin. Med. 201: 671 1955;
    PubMedGoogle Scholar
  • 20 Lanchantin G. F, Ware A. G. Identification of a thromboplastin inhibitor in serum and in plasma. J. clin. Invest. 32: 381 1953;
    CrossrefPubMedGoogle Scholar
  • 21 Margolis J. Glass surface blood coagulation. Nature No 4537: 10 1956;
    PubMedGoogle Scholar
  • 22 Margolis J. Plasma pain-producing substance and blood clotting. Nature No. 1464: 16 1957; a.
    PubMedGoogle Scholar
  • 23 Margolis J. Initiation of blood coagulation by glass and related surfaces. J. Physiol. 137: 95 1957; b.
    CrossrefPubMedGoogle Scholar
  • 24 McClaughry R. I. The specificity of antithromboplastic activity. J. Mich med. Soc. 49: 685 1950;
    PubMedGoogle Scholar
  • 25 Morawitz P. The chemistry of blood coagulation. Charles C. Thomas; Springfield, Ill., U. S. A: 1905
    Google Scholar
  • 26 Olsson P. Variations in antithrombin activity in plasma after major surgery. Acta chir. scand. 126: 24 1963;
    PubMedGoogle Scholar
  • 27 Owren P. A. The coagulation of blood. Investigations on a new clotting factor. Acta med. scand. 128. Suppl. 194 1947
    PubMedGoogle Scholar
  • 28 Owren P. A. Le complexe activateur de la prothrombine et son intérêt clinique. Rev. Hémat. 06: 135 1951;
    PubMedGoogle Scholar
  • 29 Owren P. A. The present state of the converting and accelerator factors in prothrombin conversion. Int. Conference on Thrombosis and Embolism. P. 65; Schwabe & Co, Basel: 1955
    Google Scholar
  • 30 Ratnoff O. D, Davie E. W. The activation of Christmas factor (factor IX) by activated plasma thromboplastin antecedent (activated factor XI). Biochemistry 01: 677 1962;
    CrossrefPubMedGoogle Scholar
  • 31 Ratnoff O. D, Davie W, Mallett D. L. Studies on the action of Hageman factor: Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J. clin. Invest. 40: 803 1961;
    CrossrefPubMedGoogle Scholar
  • 32 Ratnoff R. D, Rosenblum J. M. Role of Hageman factor in the initiation of clotting by glass. Evidence that glass frees Hageman factor from inhibition. Amer. J. Med. 20: 160 1958;
    PubMedGoogle Scholar
  • 33 Schimpf K. l, Mülhäuser W, Tenpel R. La place de Tantithrombokinase tissulaire dans la coagulation sanguine. Hémostase. I: 63 1961;
    PubMedGoogle Scholar
  • 34 Schneider C. L. The inactivation of placental toxin by human serum. Amer. J. Physiol. 146: 140 1946;
    PubMedGoogle Scholar
  • 35 Seegers W. H. Prothrombin. 342 350. Harvard Univ. Press; Cambridge: 1962
    Google Scholar
  • 36 Seegers W. H, Marciniak E. Inhibition of autoprothrombin C activity with plasma. Nature 193: 1188 1962;
    PubMedGoogle Scholar
  • 37 Seegers W. H, Schröer H, Kagami M. Inactivation of purified autoprothrombin I with antithrombin. Canad. J. Biochem. 42: 1425 1964;
    CrossrefPubMedGoogle Scholar
  • 38 Soulier J. P. Les inhibiteur natural de la coagulation. Sang. 30: 262 1959;
    PubMedGoogle Scholar
  • 39 Soulier J. P. Natural inhibitors. Progress in coagulation. 38 Schattauer, Stuttgart: 1962
    Google Scholar
  • 40 Soulier J. P, Wartelle O, Ménaché D. Hageman trait and PTA deficiency ; the role of contact of blood with glass. Brit. J. Haemat. 05: 121 1959;
    CrossrefPubMedGoogle Scholar
  • 41 Spaet T. H, Garner E. S. Inactivation of thromboplastin in human blood. J. clin Invest. 34: 1807 1955;
    CrossrefPubMedGoogle Scholar
  • 42 Spaet T. H, Cintron J. Induction in rabbits of activity against human blood thromboplastin. Blood 15: 772 1960;
    PubMedGoogle Scholar
  • 43 Spurling C. L, King PDW. Studies on thromboplastin generation. J. Lab. clin. Med. 44: 336 1954;
    PubMedGoogle Scholar
  • 44 Straub W, Duckert F. The formation of extrinsic prothrombin activation. Thrombos. Diathes. haemorrh. (Stuttg) 05: 402 1961;
    PubMedGoogle Scholar
  • 45 Thomas L. Studies on the intravascular thromboplastic effect of tissue suspensions in mice. Bull. John Hopk. Hosp. 81: 23 1947;
    PubMedGoogle Scholar
  • 46 Wagner R. H, Brannon Jr. WM, Brinkhous K. M. Anti-accelerator (anticonvertin) activity of canine plasma and serum fractions. Fed. Proc. 12: 405 1953;
    PubMedGoogle Scholar
  • 47 Wagner B. H, Brannon Jr. WM, Brinkhous K. M. Anti-accelerator (anticonvertin) activity of canine plasma and serum. Proc. Soc. exp. Biol. (N. Y) 89: 266 1955;
    CrossrefPubMedGoogle Scholar
  • 48 Waaler B. A. Contact activation in the intrinsic blood clotting system. Scand. J. clin. Lab. Invest. 11. Suppl. 37 1959
    PubMedGoogle Scholar